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Background
Biologic agents may cause auto-antibody formation and
drug induced lupus but no paediatric guidelines exist
regarding monitoring of auto-antibodies. The UK Royal
College of Nursing Guidance advises checking ANA and
anti-dsDNA before starting biologic treatment and
repeating anti-dsDNA if concerned.
The Alder Hey protocol tested an autoantibody profile
(Table 1, 2) 3-6 monthly for data entry for the British
Paediatric and Adolescent Rheumatology (BSPAR) Bio-
logics and New Drugs Registry (BDNR) and children
with day ward IV biologic administration often had
automatic antibodies testing 4-6 weekly.
Aim
To analyse frequency of antibody positivity in rheuma-
tology patients on biologics in order to estimate costs
and to devise a rational protocol for test frequency.
Method
A retrospective audit of a 2 year period, August 2008 to
July 2010. All patients on biologics were included with
data on auto-antibodies collated using the hospital com-
puter system.
Results
111 children were receiving biologic therapy and 2511
auto-antibodies were tested at a cost of over £26,000.
Alder Hey Children’s NHS Foundation Trust, UK
Table 1
Diagnosis of patients receiving biologic therapies N
o of Patients
JIA 102
SLE 1
JDM 2
Scleroderma 2
Uveitis (without arthritis) 2
Systemic sclerosis 1
Sarcoid vasculitis 1
Table 2
Antibody N
o of children with positive results / N
o
children with antibodies checked [%]
N
o of positive antibodies / N
o
antibodies checked [%]
Comments
ANA 80 / 111 [72%] 431 / 540 [79%] 36 children [32%] ANA always +ve; 44 children
ANA sometimes +ve but not always.
Anti ENA 4 / 109 [<4%] 18 / 501 [<4%] Always non-specific. Negative on subsequent
testing.
Anti dsDNA 1/ 111 [<1%] 2 / 510 [<1%] Negative on subsequent testing.
ANCA 14 / 41 [34%] 25 / 66 [38%] Always non-specific (non PR3 / MPO).
Anticardiolipin 6 / 98 [6%] 8 / 894 [<1%] Negative on subsequent testing.
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With the exception of ANA antibody, all other antibody
tests were usually negative. Those that were positive
tended to be non specific (ie. ANCA non-PR3 / MPO;
ENA no specific specificity) and/or were negative on
subsequent testing. The results did not alter patient care
yet costs are significant. This audit would suggest that
antibody tests are checked too frequently at Alder Hey
Hospital. A new protocol in development is likely to
recommend testing auto-antibodies annually in the
absence of clinical signs / symptoms of lupus.
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